NASDAQ:PETQPetIQ Stock Price, Forecast & News

$30.31

+0.14 (+0.46 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$30.11

Now: $30.31▼

$31.83

50-Day Range

$22.13

MA: $26.89▼

$30.75

52-Week Range

$15.83

Now: $30.31▼

$36.33

Volume351,853 shs

Average Volume379,785 shs

Market Capitalization$860.20 million

P/E RatioN/A

Dividend YieldN/A

Beta1.68

PetIQ, Inc. operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers Rx pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and OTC medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars. It also provides health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company offers its products primarily under the PetIQ, PetAction Plus, Advecta, PetLock Plus, and TruProfen brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 39 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It sells its products through approximately 60,000 points of distribution across retail and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
PetIQ has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $33.50, PetIQ has a potential upside of 10.5% from its current price of $30.31.
Amount of Analyst Coverage
PetIQ has only been the subject of 3 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
PetIQ has received 278 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
PetIQ has received 279 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
PetIQ has received 50.09% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about PetIQ and other stocks. Vote “Outperform” if you believe PETQ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PETQ will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
PetIQ does not currently pay a dividend.
Dividend Growth
PetIQ does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PetIQ insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,929.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 24.12% of the stock of PetIQ is held by insiders.
Percentage Held by Institutions
94.75% of the stock of PetIQ is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for PetIQ are expected to grow by 84.91% in the coming year, from $1.06 to $1.96 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PetIQ is -46.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PetIQ is -46.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
PetIQ has a PEG Ratio of 1.13. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
PetIQ has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.18 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Drugs, proprietaries, & sundries

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PETQ

Previous Symbol

CUSIPN/A

CIK1668673

Webwww.petiq.com

Phone208-939-8900

Debt

Debt-to-Equity Ratio1.04

Current Ratio2.85

Quick Ratio1.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio28.59

P/E Growth1.13

Sales & Book Value

Annual Sales$709.43 million

Price / Sales1.21

Cash Flow$1.46 per share

Price / Cash Flow20.82

Book Value$11.60 per share

Price / Book2.61

Profitability

EPS (Most Recent Fiscal Year)$1.07

Net Income$-11,450,000.00

Net Margins-2.03%

Return on Equity8.28%

Return on Assets4.15%

Miscellaneous

Employees1,866

Outstanding Shares28,380,000

Market Cap$860.20 million

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive PETQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PETQ and its competitors with MarketBeat's FREE daily newsletter.

PetIQ (NASDAQ:PETQ) Frequently Asked Questions

How has PetIQ's stock been impacted by COVID-19 (Coronavirus)?

PetIQ's stock was trading at $22.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PETQ shares have increased by 34.2% and is now trading at $30.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PetIQ?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PetIQ.

When is PetIQ's next earnings date?

PetIQ is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for PetIQ.

How were PetIQ's earnings last quarter?

PetIQ Inc (NASDAQ:PETQ) released its earnings results on Tuesday, March, 10th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.18. The business earned $154.34 million during the quarter, compared to analyst estimates of $134.80 million. PetIQ had a negative net margin of 2.03% and a positive return on equity of 8.28%. View PetIQ's earnings history.

What guidance has PetIQ issued on next quarter's earnings?

PetIQ issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $815 million, compared to the consensus revenue estimate of $807.68 million.

What price target have analysts set for PETQ?

3 analysts have issued 1-year target prices for PetIQ's stock. Their forecasts range from $32.00 to $35.00. On average, they expect PetIQ's stock price to reach $33.50 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price. View analysts' price targets for PetIQ.

Has PetIQ been receiving favorable news coverage?

Media coverage about PETQ stock has been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. PetIQ earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutPetIQ.

Who are some of PetIQ's key competitors?

Some companies that are related to PetIQ include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Trxade Group (TRXD), MultiCell Technologies (MEDS) and biOasis Technologies (BIOAF). View all competitors.

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Intel (INTC), Advanced Micro Devices (AMD), CVS Health (CVS), Exelixis (EXEL), salesforce.com (CRM), Crispr Therapeutics (CRSP) and IBM (IBM).

Who are PetIQ's key executives?

PetIQ's management team includes the following people:

Mr. McCord Christensen, Chairman & CEO (Age 47)
Ms. Susan Sholtis, Pres (Age 53)
Mr. John Newland, Chief Financial Officer (Age 55)
Mr. Robert Michael Herrman, Gen. Counsel & Sec.
Mr. Adam Fellers, Sr. VP of Sales

When did PetIQ IPO?

(PETQ) raised $86 million in an IPO on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair served as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

Who are PetIQ's major shareholders?

PetIQ's stock is owned by many different institutional and retail investors. Top institutional investors include Fred Alger Management LLC (11.49%), Waddell & Reed Financial Inc. (6.18%), BlackRock Inc. (5.70%), Wasatch Advisors Inc. (5.57%), Prentice Capital Management LP (3.34%) and Ensign Peak Advisors Inc (2.78%). Company insiders that own PetIQ stock include Ecp Helios Partners Iv, LP, James Nathan Clarke, John Newland, Mccord Christensen, Robert Michael Herrman, Susan Sholtis and Will Santana. View institutional ownership trends for PetIQ.

Which institutional investors are selling PetIQ stock?

PETQ stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Peregrine Capital Management LLC, Russell Investments Group Ltd., Waddell & Reed Financial Inc., WINTON GROUP Ltd, AMI Asset Management Corp, and Wells Fargo & Company MN. Company insiders that have sold PetIQ company stock in the last year include Susan Sholtis, and Will Santana. View insider buying and selling activity for PetIQ.

Which institutional investors are buying PetIQ stock?

PETQ stock was bought by a variety of institutional investors in the last quarter, including FDx Advisors Inc., FDx Advisors Inc., Fred Alger Management LLC, Driehaus Capital Management LLC, Aperture Investors LLC, Prentice Capital Management LP, Geode Capital Management LLC, and Nepsis Inc.. Company insiders that have bought PetIQ stock in the last two years include James Nathan Clarke, John Newland, and Robert Michael Herrman. View insider buying and selling activity for PetIQ.

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $30.31.

How big of a company is PetIQ?

PetIQ has a market capitalization of $860.20 million and generates $709.43 million in revenue each year. The company earns $-11,450,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. PetIQ employs 1,866 workers across the globe.

What is PetIQ's official website?

The official website for PetIQ is www.petiq.com.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at 208-939-8900 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff